Upregulation of tRF‐19‐J in Anti‐Aβ Therapy‐Related ARIA Among Alzheimer's Disease Patients and Its Role in Promoting Ubiquitin‐Mediated Degradation of Connexin 43 in Brain Endothelial Cells

tRF-19-J is markedly upregulated in ARIA patients undergoing anti-Aβ therapy and facilitates the ubiquitin-mediated degradation of Cx43, suggesting its involvement in BBB permeability disruption. Given its stable expression in peripheral blood, tRF-19-J holds potential as a blood-based biomarker for predicting ARIA in AD patients receiving anti-Aβ treatment, laying the groundwork for future research into its predictive and therapeutic value.